U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07411781) titled 'PIN in Combination With Sintilimab in Previously Treated pMMR/MSS CRC With Hepatic Metastases' on Feb. 09.
Brief Summary: In this single-center,open-label, phase I study, the safety and efficacy of PIN in combination with anti-programmed cell death -1 (anti-PD1) antibody therapeutic regimen (sintilimab) will be evaluated in patients with advanced proficient mismatch repair/microsatellite stable (pMMR/MSS) colorectal cancer (CRC) with hepatic metastases . A total of 25 to 30 patients are planned to be enrolled and receive PIN plus sintilimab combined treatment. It aims to:
1).assess the safety and antitumor effects of the above comb...